<?xml version='1.0' encoding='utf-8'?>
<document id="23428312"><sentence text="Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro."><entity charOffset="43-54" id="DDI-PubMed.23428312.s1.e0" text="rilpivirine" /></sentence><sentence text="The objective of this study was to assess the drug-drug interaction potential of the new non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine in vitro"><entity charOffset="144-155" id="DDI-PubMed.23428312.s2.e0" text="rilpivirine" /></sentence><sentence text=" The following were evaluated: P-glycoprotein (P-gp/ABCB1) inhibition by calcein assay; breast cancer resistance protein (BCRP/ABCG2) inhibition by pheophorbide A efflux; and inhibition of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 by 8-fluorescein-cAMP uptake" /><sentence text=" Inhibition of cytochrome P450 enzymes was assessed using commercially available kits" /><sentence text=" Substrate characteristics were evaluated by growth inhibition assays in MDCKII cells overexpressing particular ABC transporters" /><sentence text=" Induction of drug-metabolising enzymes and transporters was quantified by real-time RT-PCR in LS180 cells, and activation of pregnane X receptor (PXR) by a reporter gene assay" /><sentence text=" Rilpivirine significantly inhibited P-gp (IC(50) = 13"><entity charOffset="1-12" id="DDI-PubMed.23428312.s7.e0" text="Rilpivirine" /></sentence><sentence text="1 ± 6" /><sentence text="8 μmol/L), BCRP (IC(50) = 1" /><sentence text="5 ± 0" /><sentence text="3 μmol/L), OATP1B1 (IC(50) = 4" /><sentence text="1 ± 1" /><sentence text="8 μmol/L), OATP1B3 (IC(50) = 6" /><sentence text="1 ± 0" /><sentence text="9 μmol/L), CYP3A4 (IC(50) = 1" /><sentence text="3 ± 0" /><sentence text="6 μmol/L), CYP2C19 (IC(50) = 2" /><sentence text="7 ± 0" /><sentence text="3 μmol/L) and CYP2B6 (IC(50) = 4" /><sentence text="2 ± 1" /><sentence text="6 μmol/L)" /><sentence text=" Growth inhibition assays indicate that rilpivirine is not a substrate of P-gp, BCRP, or multidrug resistance-associated proteins 1 and 2"><entity charOffset="40-51" id="DDI-PubMed.23428312.s22.e0" text="rilpivirine" /></sentence><sentence text=" In LS180 cells, rilpivirine induced mRNA expression of ABCB1, CYP3A4 and UGT1A3, whereas ABCC1, ABCC2, ABCG2, OATP1B1 and UGT1A9 were not induced"><entity charOffset="17-28" id="DDI-PubMed.23428312.s23.e0" text="rilpivirine" /></sentence><sentence text=" Moreover, rilpivirine was a PXR activator"><entity charOffset="11-22" id="DDI-PubMed.23428312.s24.e0" text="rilpivirine" /></sentence><sentence text=" In conclusion, rilpivirine inhibits and induces several relevant drug-metabolising enzymes and drug transporters, but owing to its low plasma concentrations it is most likely less prone to drug-drug interactions than older NNRTIs"><entity charOffset="16-27" id="DDI-PubMed.23428312.s25.e0" text="rilpivirine" /></sentence><sentence text="" /></document>